Dr. Sirgo: BioDelivery Sciences was founded in 1996. It was a spinoff of the University of Medical and Dental School of New Jersey. Our BEMA technology was brought to BioDelivery Sciences in 2004, when BioDelivery acquired Arius Pharmaceuticals, who was the licensee of the BioErodible Mucoadhesive (BEMA) technology.
TWST: Tell us about your drug delivery systems.
Dr. Sirgo: We have two proprietary drug delivery systems in the company. One is BEMA, which we acquired from a company called Atrix Pharmaceuticals. The Bioral technology, which is the second platform, was developed internally. We use these to reinvent proven therapeutics. We take generic drug substances, and we place them in these technologies to create products that we think meet unmet market needs. We look towards the markets, and we have a particular focus in oncology supportive care and pain. So we try to apply the technologies to those two therapeutic categories, and that's what we have done with our current portfolio.
Tickers included in this excerpt: BDSI
For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.